BeBetter Med Inc.

EGFR-Mutated NSCLC Pipeline Expands with 30+ Therapies as FDA Approves Dato-DXd and J&J Combination Shows Survival Benefit

- The FDA granted accelerated approval to Dato-DXd in June 2025 for adults with locally advanced or metastatic EGFR-mutated NSCLC who progressed after prior EGFR-targeted therapies and platinum-based chemotherapy. - Johnson & Johnson's Phase 3 MARIPOSA study demonstrated that the combination of RYBREVANT and LAZCLUZE significantly improved overall survival compared to osimertinib in EGFR-mutated NSCLC patients. - Over 25 companies are developing 30+ therapies for EGFR-mutated NSCLC across various clinical phases, including novel small molecules, monoclonal antibodies, and combination treatments. - Recent clinical milestones include BlossomHill Therapeutics initiating the SOLARA Phase 1/2 trial for BH-30643 and AstraZeneca receiving Priority Review for Dato-DXd's BLA application.